Benzinga | Oct 13, 2021 01:38PM EDT

Lexaria Bioscience Reports Recent Oral THC Absorption Study Revealed Its DehydraTECH Required 15 Mins. To Deliver THC Levels In Blood Plasma

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that its recent oral tetrahydrocannabinol ("THC") absorption study THC-A21-1 revealed that DehydraTECHTM-THC delivered via oral ingestion required only 15 minutes to deliver THC levels in blood plasma comparable to levels achieved at 45 minutes with concentration-matched controls.

During the study DehydraTECH-THC delivered more THC into bloodstream than the industry standard medium chain triglyceride ("MCT" or "coconut oil") based control formulation from the 2-minute mark onwards, then dropped rapidly to the same level as the MCT control by the 6-hour mark.

According to Harvard Medical School, the most common use for medical cannabis in the US is for the control of pain. Chronic pain is associated with nerve disorders and multiple sclerosis, and users are frequently cited as responding to a cannabis treatment program, without the highly addictive or sedating effects of opiates. Lexaria's investigation of enhanced delivery characteristics of THC utilizing DehydraTECH technology is focused on medical applications.

Key pharmacokinetic ("PK") findings from the study are tabulated below demonstrating statistically significant improvements in peak and total THC delivery (i.e., maximum concentration or Cmax and total area under the curve up to the point of the last measurement or AUClast respectively):

DehydraTECH-THC Cmax&# MCT DehydraTECH-THCAUClast&# MCT (Coconut Oil)x2A; % Improvement Control x2A;* % Improvement Control THC THC(ng/mL) (hr?ng/mL) (hr?ng/mL) (ng/mL)

178.6 +- 81.1 539.2 +- 190.9 84.7 +-110.9% 43.9 96.5% 274.4 +- 106.9

(p=0.026) (p=0.013)

"The cannabis industry continues to use outdated formulations and processes that ignore the needs of modern THC users," said Chris Bunka, CEO of Lexaria Bioscience Corp. "THC users today include recreational, medicinal and pharmaceutical users, all of whom need technology that doesn't rely on harmful delivery methods such as smoking but still provides rapid onset and high bioavailability which common oral formats do not offer. Our study findings demonstrated rapid delivery, increased overall THC delivery, and higher brain tissue delivery; all of which is consistent with the wants and needs of THC customers."

DehydraTECH processing continues to prove its ability to deliver drugs more effectively not just into the bloodstream, but also into brain tissue. Only two time-points were selected to collect brain tissue absorption samples, meaning blood concentration levels likely had peaked much earlier, but DehydraTECH-THC brain tissue levels were effectively twice as high as the MCT controls, mirroring what was seen with the blood level readings achieved during the study:

DehydraTECH THC Improvement % Coconut-Oil Control THCBrain Absorption (ng/g) (ng/g)

121.0 +- 92.68-Hours 59.6 +- 20.5 103.0%

14.4 +- 10.324-Hours 6.9 +- 5.2 108.7%

About Study THC-A21-1